This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newcomb, E. W. Articles by Potmesil, M. Search for Related Content PubMed PubMed Citation Articles by Newcomb, E. W. Articles by Potmesil, M.

Frequent Homozygous Deletions of D13S218 on 13q14 in B-Cell Chronic Lymphocytic Leukemia Independent of Disease Stage and Retinoblastoma Gene Inactivation¹

Departments of Pathology [E. W. N., A. T., A. S., S. Y. L.] and Radiology [M. P.], New York University School of Medicine and Kaplan Comprehensive Cancer Center, New York, New York 10016

A correlative study has been performed to delineate further the role of the Rb gene in the disease B-cell chronic lymphocytic leukemia (B-CLL). First, we examined DNAs from B cells from 140 B-CLL patients representing all Rai stages of disease for the loss of 13q14 using two microsatellite markers mapping distal to the Rb locus. Loss of heterozygosity (LOH) of D13S133 was infrequent, occurring in 5 of 140 (4%) patients. The frequency for LOH of D13S218 was 33 of 140 (24%) samples and was independent of Rai stage of disease. Rb protein was detected in 19 of 23 (83%) samples. Of 4 patients lacking detectable Rb gene expression, only one showed LOH of D13S218. Rb protein levels varied from undetectable to high in samples with or without LOH for D13S218, and the levels were also independent of Rai stage of disease. Our findings support the role of DBM on 13q14, rather than Rb, as the candidate tumor suppressor gene that is frequently targeted for deletion in B-CLL. In addition, the data suggest that other mechanism(s) contribute to altered Rb expression detected in one-fourth of B-CLL B-cells.

¹ Supported in part by National Cancer Institute Grants CA53572, CA50529, and CA54484; the Wendy Will Case Cancer Fund, Inc.; and the Maria Slater Society for Research in Leukemia.

² To whom requests for reprints should be addressed, at Department of Pathology and Kaplan Cancer Center, New York University Medical Center, 550 First Avenue, New York, NY 10016.

Received 3/20/95. Accepted 4/ 5/95.

This article has been cited by other articles:

				R. La Starza, I. Wlodarska, A. Aventin, D. Falzetti, B. Crescenzi, M.F. Martelli, H. Van den Berghe, and C. Mecucci Molecular Delineation of 13q Deletion Boundaries in 20 Patients With Myeloid Malignancies Blood, January 1, 1998; 91(1): 231 - 237. [Abstract] [Full Text] [PDF]